β2-Microglobulin levels in cancerous and other disease states

Prognostic Values of Various Clinical Factors and Genetic Subtypes for Diffuse Large B-cell lymphoma Patients: A Retrospective Analysis of 227 Cases

“…β2-microglobulin (β2-M), a 11kDa non-glycosylated protein, exists in all nucleated cells (Cunningham et al, 1973;Güssow et al, 1987) and is involved in the regulation of the host immune response (Townsend et al, 1986;Pedersen et al, 1994), as well as a growth factor and signaling molecule in cancer cells. β2-M expression increases during progression of human prostate cancer (Gross et al, 2007), breast cancer (Teasdale et al, 1977), renal cancer (Hemmingsen and Skaarup, 1977), lung cancer (Shuster et al, 1976), colon cancer (Ward et al, 2008), and a number of liquid tumors (Yang et al, 2006).…”

Serum β 2-microglobulin in myelomatosis: potential value in stratification and monitoring

“…Hence any new biochemical test, to be considered seriously for the stratification of multiple myelomatosis, must be capable of providing information comparable to the more complex systems in current use. There is growing evidence that serum P2-microglobulin (32-m) level is often increased in multiple myelomatosis (Shuster et al, 1976;Belleville et al, 1978). However, P2-m is a low-mol.…”

Expression of beta-2-microglobulin by nasopharyngeal carcinoma

“…This may be due to more active cellular proliferation in tumours with poorer histological differentiation. Similar findings however were not evident in non-Hodgkin's lymphoma (Anderson et al, 1983 (Teasdal et al, 1977) and myeloma (Hagberg et al, 1983;Alexanian et al, 1985), and is thought to be due to increased cell turnover (Karlsson et al, 1980) and/or augmented immune response by lymphocytes to the neoplasm (Forman, 1982;Rashid et al, 1980;Karlsson et al, 1980;Shuster et al, 1976).…”